Neuroprotective mechanisms and translational potential of therapeutic hypothermia in the treatment of ischemic stroke

Jin Hwan Lee, James Zhang, Shan Ping Yu
Department of Anesthesiology, Emory University School of Medicine, Atlanta, GA, USA; Veteran’s Affair Medical Center, Center for Visual and Neurocognitive Rehabilitation, Atlanta, GA, USA

How to cite this article: Lee JH, Zhang J, Yu SP (2017) Neuroprotective mechanisms and translational potential of therapeutic hypothermia in the treatment of ischemic stroke. Neural Regen Res 12(3):341-350.

Open access statement: This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

Funding: This paper was supported by an American Heart Association (AHA) Postdoctoral Fellowship 15POST25680013 (JHL), NIH grants N085568 (SPY), and a VA Merit grant RX000666 (SPY).

Abstract
Stroke is a leading cause of disability and death, yet effective treatments for acute stroke has been very limited. Thus far, tissue plasminogen activator has been the only FDA-approved drug for thrombolytic treatment of ischemic stroke patients, yet its application is only applicable to less than 4–5% of stroke patients due to the narrow therapeutic window (< 4.5 hours after the onset of stroke) and the high risk of hemorrhagic transformation. Emerging evidence from basic and clinical studies has shown that therapeutic hypothermia, also known as targeted temperature management, can be a promising therapy for patients with different types of stroke. Moreover, the success in animal models using pharmacologically induced hypothermia (PIH) has gained increasing momentum for clinical translation of hypothermic therapy. This review provides an updated overview of the mechanisms and protective effects of therapeutic hypothermia, as well as the recent development and findings behind PIH treatment. It is expected that a safe and effective hypothermic therapy has a high translational potential for clinical treatment of patients with stroke and other CNS injuries.

Key Words: stroke; therapeutic hypothermia; drug-induced hypothermia; ischemia; cell death; inflammation

Introduction
Although recently stroke fell from the fourth to the fifth leading cause of human death in the United States, each year there are still approximately 750,000 individuals who suffer a new or recurrent stroke (ischemic or hemorrhagic) (Writing Group et al., 2016). About 610,000 of them encounter a primary stroke attack, and 185,000 have recurrent stroke events. A stroke attack occurs every 40 seconds, resulting in stroke-related deaths every 4 minutes in the United States. Due to the increasing aged population, the American Heart Association (AHA) has projected that healthcare costs associated with stroke would increase dramatically in the next 20 years according to the increased incidence and prevalence of stroke.

Despite tremendous advancements in understanding the pathogenesis and cellular/molecular mechanisms of stroke over the last few decades, thrombolytic therapy using tissue plasminogen activator (tPA) has been the only drug approved by the Food and Drug Administration (FDA) for treating acute ischemic stroke (Group, 1995). Although recent data show that the rates of tPA application has been increased between 2005 and 2009, still only < 4% of all stroke patients can benefit from the thrombolytic treatment. This is mainly due to the required early treatment and a high risk of hemorrhagic transformation associated with tPA applications (Adeoye et al., 2011). Thus, there is an urgent need to develop new therapies that have wider therapeutic windows and are more effective for more stroke patients (Shobha et al., 2011).

Over the past two decades, many neuroprotective drugs and treatments have failed the clinical translation from animal models to clinical practice due to the lack of efficacy and, in some cases, intolerable side-effects (Cheng et al., 2004). With the increasing understanding of the cellular and molecular injurious pathways and their interplays in ischemic cascades, it is now increasingly recognized that the conventional strategy of targeting a specific inhibitory or excitatory neuronal receptor or ion channel or a single signaling pathway/gene is far from enough to battle the overwhelming pathophysiologicalescades that occur acutely, sub-acutely, and even chronically after a stroke attack. Thus, a global protection paradigm that covers different cell types including neuronal and non-neuronal cells and multiple signaling pathways is necessary to achieve clinically meaningful benefits for stroke patients.

Compelling evidence from pre-clinical research in animal models demonstrated marked protective effects of mild to moderate hypothermia (therapeutic hypothermia) against...
ischemic and hemorrhagic brain damage (Darwazeh and Yan, 2013; Chamorro et al., 2016). Therapeutic hypothermia ameliorates brain damage through inhibition of multiple pathways such as oxidative stress, inflammatory responses, metabolic disruption, and cell death signals (Katz et al., 2004; Choi et al., 2012). Furthermore, therapeutic hypothermia therapy improves functional outcomes in animal models of stroke and traumatic brain injury (TBI) (Polderman et al., 2002; Choi et al., 2012; Lee et al., 2014). In humans, multiple clinical trials involving both surface cooling and endovascular hypothermia have been effective in decreasing certain quantitative metrics that correspond with functional outcomes after TBI, including intracerebral pressure (ICP) and the mean diffusion-weighted imaging (DWI) lesion growth (Schwab et al., 1998a, b, 2001; De Georgia et al., 2004). In clinical practice, mild to moderate hypothermia (3–5°C reduction) is safe and has been used for the treatments of cardiac arrest and hypoxic-ischemic encephalopathy (Dae et al., 2003; Xiao et al., 2013). In fact, therapeutic hypothermia has been incorporated in the American Heart Association (AHA) guidelines for post-resuscitation care for more than 10 years (Sugerman and Abella, 2009). Thus, both pre-clinical and clinical evidence supports that therapeutic hypothermia has a promising potential to be an effective treatment for acute brain injury such as stroke and TBI (Schwab et al., 1998b, 2001; De Georgia et al., 2004; van der Worp et al., 2007; Torok et al., 2009; Kim et al., 2011; Yenari and Han, 2012; Lee et al., 2016a). Currently, there is no other experimental stroke therapy that has demonstrated such strong potential in both basic and clinical research, although challenges on the efficacy and the mechanism of action call for future and more specific investigations (Tahir and Pabaney, 2016). This review will focus on emerging concepts in the protective mechanisms of therapeutic hypothermia for treating patients with stroke, as well as highlighting pharmacologically induced hypothermia (PIH), or drug-induced cooling treatments, that can be applied as an acute hypothermic treatment with some unique advantages.

Mechanisms of Therapeutic Hypothermia against Ischemia-induced Brain Damage

Excitotoxicity

Glutamate mediates excitatory synaptic transmission through the activation of ionotropic glutamate receptors that are sensitive to N-methyl-D-aspartate (NMDA), α-aminoo-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), or kainate in the nervous system. The excitatory transmission mediates normal information processing and neuronal plasticity (Won et al., 2002). It has been well established that excessive activation of glutamate receptors mediates the initial step in excitotoxicity. Upon an ischemic insult, the interruption of blood supply in the brain causes the deprivation of oxygen and glucose, leading to impaired energy metabolism (Choi, 1992; Dugan and Choi, 1994). Consequently, it increases glutamate release through membrane depolarization and the subsequent activation of the voltage gated Ca²⁺ channels (Choi, 1992; Dugan and Choi, 1994). Due to impaired energy synthesis, reuptake of glutamate is also interfered, which results in the excess accumulation of synaptic glutamate. The sustained over-activation of the ionotropic glutamate receptors leads to neuronal death, mostly due to necrotic cell death mechanism.

Recent reports have shown that therapeutic hypothermia prevents the accumulation or release of glutamate (Zhao et al., 2007a; Yenari and Han, 2012). Also, body temperature influences glutamate excitotoxicity during the acute phase of stroke, indicating that the release of these neurotransmitters is temperature dependent (Campos et al., 2012). Hypothermia can directly affect excitotoxicity through regulating the glutamate receptor 2 (Glur2) subunit of AMPA receptors (Colbourne et al., 2003). Hypothermia recovers the downregulation of GluR2 in hippocampal CA1 neurons after global cerebral ischemia in gerbils. After stroke, hypothermia significantly decreases brain glycine levels, which is needed to activate NMDA receptors and accelerate the function of NMDA receptors (Johnson and Ascher, 1987; Krvivishvili, 2002). Additionally, hypothermia reduces the number of AMPA and NMDA receptors expressed on hippocampal neurons after stroke, which is associated with decreased infarct volume (Friedman et al., 2001; Li et al., 2011). Hypothermia also abates spreading depolarization that occurs after ischemic stroke by reducing the release of excitatory amino acids (EAA) (Nakashima and Todd, 1996).

Oxidative stress

Neurons are exposed to a minimum level of free radicals from both exogenous and endogenous sources in the normal condition (Dugan and Choi, 1994; Won et al., 2002). However, excess accumulation of reactive oxygen species leads to the damage of basic components for cell function and survival. Because the storage capacity of oxygen is limited in the brain, as well as there being a high probability of lipid peroxidation, neurons can be vulnerable to the change of free radical levels when oxygen supply is interrupted. Following stroke, increases in arachidonic acid, nitric oxide, glutamate, and over-activation of glutamate receptors rapidly develop in the ischemic tissue, which coincides with the production of free oxygen radicals such as superoxide ($O_2^-$), peroxynitrite ($NO_2^-$), hydrogen peroxide ($H_2O_2$), and hydroxyl radicals ($OH^-$), resulting in neuronal death (Dugan and Choi, 1994; Globus et al., 1995b; Yenari and Han, 2012). The production of free radicals after stroke is temperature-dependent, and the suppression of free radical production is linearly proportional to the decreased temperature (Globus et al., 1995a; Hall, 1997). As a result, hypothermia can significantly reduce the production of free radicals and maintain the endogenous antioxidant activity in injured cells (Globus et al., 1995a).

Apoptosis

Necrosis and apoptosis are two major forms of neuronal cell death after ischemic stroke. Necrosis is a form of cell injury where edema and cellular inflammatory responses occur,
leading to excitotoxic death. Apoptosis is the main type of programmed cell death caused by activation of a cascade of intracellular pathways. This cell death mechanism is regulated by the culmination of interactions between pro-apoptotic and anti-apoptotic signaling genes (Mattson, 2000). Hypoxia and ATP depletion trigger neurons to activate the apoptotic regulatory proteins and several cellular processes, which include mitochondria dysfunction, activation of caspase enzymes, acidosis, calcium imbalance, and other cellular energy metabolism disorders (Won et al., 2002; Xu et al., 2002). These apoptotic events are mostly responsible for some delayed and secondary brain injuries.

Experimental models of ischemia have shown that therapeutic hypothermia prevents neuronal apoptosis through decreasing p53 protein, a transcription factor which activates apoptosis and pro-apoptotic proteins, including Bak, Bax, and NAD depletion (Bargonetti and Manfredi, 2002; Choi et al., 2012; Lee et al., 2014). Hypothermia regulates the levels of apoptotic related genes such as B-cell lymphoma-2 (BCL-2), cytochrome C, and tumor necrosis factor (TNF) pathway genes (Bossenmeyer-Pourie et al., 2000; Zhao et al., 2004, 2007b; Liu et al., 2008). After stroke, hypothermia stimulates anti-apoptotic proteins in the Bcl-2 family, causes the reduction of cytochrome c release into the cytosol, inhibits caspase activation, and thus enhances cell survival (Prakasa Babu et al., 2000; Zhao et al., 2004). Experimental animal models have shown that hypothermia has a beneficial effect on the dysfunction of ATP-dependent Na+/K+ pumps and Na+, K+, and Ca2+ channels and reduces the influx of calcium into the cells, abating neuronal damage (Siesjo et al., 1989; Hall, 1997).

**Autophagy**

Autophagy is normally a physiological catabolic process for nutrient recycling, involving degradation of damaged organelles and proteins. The process is tightly regulated by autophagy signaling pathways, and alterations in this process may lead to diseases or exacerbate damage under pathological conditions. In recent years, increased autophagy has been identified as one of the pathophysiological mechanisms after ischemic stroke (Chen et al., 2014). We were one of the first groups to demonstrate that a suppressing effect of therapeutic hypothermia on autophagy contributes to the neuroprotection after ischemic stroke (Choi et al., 2012). In our investigation, autophagic activity was examined by the formation of microtubule-associated protein light chain 3 (LC3-II) and degradation levels of sequestosome 1/p62 in the penumbra region. Both autophagic factors were decreased by hypothermic treatment using the neurotensin receptor agonist ABS-201. LC3-labeled autophagosomes formation and TUNEL/LC3/NeuN triple-labeled cells were also decreased by the treatment. At about the same time, a different group reported that ischemia and reperfusion stimulate cell autophagy and cause cell death, which can be attenuated by mild hypothermia (Cheng et al., 2013). More recent papers demonstrated that hypothermia can inhibit autophagic cell death after TBI and spinal cord injury (Jin et al., 2015, 2016; Seo et al., 2015). The mechanism underlying the anti-autophagy action of therapeutic hypothermia is an active area of current research.

**Inflammation**

Inflammatory mechanisms are activated after brain ischemia and act as important mediators in the pathogenesis of stroke-induced primary and secondary injuries (Vila et al., 2000; Gelderblom et al., 2009). Although a certain level of inflammation has beneficial effects required for tissue recovery and repairing, many reports have shown that inflammation is a major pathological mechanism underlying ischemic brain injury (Lakhan et al., 2009; Jin et al., 2010). During ischemia, inflammation is characterized by the production of pro-inflammatory cytokines such as TNF-α, interleukin-1β (IL-1β), IL-6, and anti-inflammatory cytokines such as IL-10, as well as the accumulation of neutrophils and the activation of microglia in the injured brain (Huang et al., 2006). Also, ischemia-mediated neuronal damage induces the synthesis and release of chemokines, such as monocyte chemoattractant protein-1 (MCP-1), macrophage inflammatory protein-1α (MIP-1α), and IP-10 (interferon-inducible protein), which can recruit microglia, monocytes, and neutrophils into the ischemic region (Rappert et al., 2004; Wang et al., 2008; Jiang et al., 2016).

Hypothermia reduces the expressions of this pro-inflammatory immune response such as TNF-α and IL-1β, but it also regulates the expression of some anti-inflammatory cytokines such as IL-10 and transforming growth factor-β (TGF-β) (Matsui and Kakeda, 2008; Ji et al., 2016; Lee et al., 2016b). Accumulated data suggest that MCP-1 and MIP-1α play crucial roles in ischemia-mediated cellular damage. Upregulation of MCP-1 and MIP-1α were observed after ischemia; while MCP-1 knockout mice show reduced infarct volume after ischemia (Che et al., 2001; Hughes et al., 2002; Wang et al., 2008; Strecker et al., 2013). In addition, MIP-1α injection exacerbated brain infarction but a broad-spectrum chemokine receptor antagonist using viral macrophage inflammatory protein-2 (vMIP-2), prevented neuronal damage from ischemic insults (Takami et al., 2001; Wang et al., 2008). Hypothermia attenuated the expression levels of chemokines such as MCP-1 and MIP-1α (Lee et al., 2016b). Recent reports have demonstrated that hypothermia prevented inflammation-mediated cellular damage through regulating both activation of NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) and Janus kinase (JAK) and signal transducer/activator of transcription pathway (STAT) signaling.

Microglia/macrophages are highly flexible cells with diverse phenotypes that are involved in the generation of distinct effector cells and functions (Murray and Wynn, 2011; Hu et al., 2012). Various cytokines by diverse stimuli lead to the development of M1 or M2 subtypes, which can express different levels of cell surface markers and secrete mediators such as scavenger receptors, chemokines, and cytokines. Recently, we showed that hypothermia shows...
neuroprotective effects partly due to a shift from M1 to M2 type microglia cells. M1 is the classic activated state that is more associated with pro-inflammation, while M2 is more protective and associated with anti-inflammation (Cherry et al., 2014). This is especially important after brain injury, in which the transition to the M2 state not only clears out inflammation, but also initiates brain repair, and a suppressed M2 response results in greater lesion sizes following both stroke and TBI (Xiong et al., 2011; Kumar et al., 2013; Pérez-de Puig et al., 2013). In the hypothermia-treated stroke brain, there were decreased M1 type reactive factors including TNF-α, IL-1β, IL-12, IL-23, and inducible nitric oxide synthase (iNOS) and increased M2 markers such as IL-10, Fizz1, Ym1, and arginase-1 (Lee et al., 2016b). Thus, hypothermia-related regulation of microglia can ameliorate the detrimental effects of a persistent M1 type microglia, including retrograde delayed degeneration, axonal degeneration, and white matter tract injury (Wilson et al., 2004; Maxwell et al., 2006).

**Others**

**Blood-brain barrier (BBB)**

Studies have shown that cerebral ischemia-reperfusion injury causes structural and functional breakdown of the BBB, resulting in increased BBB permeability, and the extent of disruption is directly correlated with the severity and duration of the insult (Latour et al., 2004; Chen et al., 2009). BBB breakdown not only causes brain edema and hemorrhage, but also increases various cytokines and chemokines, predisposing the brain to a secondary cascade of ischemic injury. BBB disruption after stroke, TBI, or other brain injuries is caused by structural and functional impairment of components of the neurovascular unit, including tight-junction proteins, transport proteins, endothelial cells, astrocytes, and pericytes.

Hypothermia prevents the activation of proteases responsible for degrading the extracellular matrix, such as the matrix metalloproteinases (MMPs) which are known to degrade tight-junction proteins (Lakhan et al., 2013). The activity of MMPs and the consequent degradation of vascular basement membrane proteins and the extracellular matrix proteins were reduced by hypothermia (Nagel et al., 2008; Baumann et al., 2009). In addition, hypothermia increases the expression of metalloproteinase inhibitor 2 (also known as TIMP2), an endogenous MMP inhibitor.

**Neurogenesis and angiogenesis**

Recent reports have shown that hypothermia can affect regenerative activities after stroke. Moderate low temperature (32°C) preserved the stemness of neural stem cells (NSCs) and prevented cell apoptosis. It is suggested that the protective effect of moderate hypothermia is partially associated with preservation of neural stem cells (Saito et al., 2010). Prolonged hypothermia positively interacts with post-ischemic repair processes, such as neurogenesis, resulting in improved functional outcome (Silasi and Colbourn, 2011). Additionally, a few studies have reported on the effect of hypothermia on angiogenesis (Xie et al., 2007). Hypothermia reduced total infarct volume and increased endogenous brain-derived neurotrophic factor (BDNF) level. The microvessel diameter, the number of vascular branches and the vessel surface area were significantly increased in the hypothermia group, suggesting that mild hypothermia enhances angiogenesis in the ischemic brain. Despite the heightened proliferation of NSCs, other studies have suggested that endogenous neurogenesis may not contribute significantly to neuronal repairs. For example, NSCs from pools such as the subventricular zone (SVZ) may be region-specific and committed to become distinct subtypes and thus will be limited in regenerative versatility (Merkle et al., 2007). However, the increased activity of NSCs may play other roles, such as promoting plasticity following injury (Quadrato et al., 2014; Obernier et al., 2015).

**Growth factors**

Neurotrophic factors in the brain can regulate neuronal synaptic function and plasticity, cellular survival, differentiation and promote neural regeneration/repair (Wang et al., 2012; Bowling et al., 2016; Wurzelmans et al., 2017). There have been conflicting reports about the growth factor response to hypothermic treatment. Hypothermia showed strong neuroprotective effects following stroke via regulating BDNF, glial-derived neurotrophic factor (GDNF), and other neurotrophins (D’Cruz et al., 2002; Schmidt et al., 2004; Vosler et al., 2005). However, in a sheep model, hypothermia shortens the activity of insulin-like growth factor 1 (IGF-1) after hypoxia (Roelfsema et al., 2005). Furthermore, studies have reported that hypothermia may suppress the release of other growth factors, including vascular endothelial growth factor (VEGF) following in vitro hypoxia and nerve growth factor (NGF) in a mouse model of TBI (Goss et al., 1995; Coassin et al., 2010). These findings may be attributed to a decrease in overall metabolism of cells in response to hypothermia.

**Other putative mechanisms**

Given the global coverage of the temperature reductions during therapeutic hypothermia, as well as the vast array of interconnected molecular pathways, there are various other putative mechanisms that contribute towards hypothermia’s neuroprotective effects. Other mechanisms include the impact of hypothermia on cerebral metabolism and consequently cerebral perfusion (Rosomoff and Holaday, 1954). The reduction in temperatures may improve brain glucose consumption and reduce the lactate-glucose and lactate-pyruvate ratios after TBI as compared to normothermia controls (Wang et al., 2007). Another pathophysiology that arises after brain injuries like ischemic stroke is cerebral thermo-pooling, in which localized foci of the brain become hyperthermic after injury, thus making it an ideal target for hypothermia (Schwab et al., 1998b). Indeed, therapeutic hypothermia is effective at reducing thermo-pooling after ischemic stroke and in other pathological cases, such as influenza encephalitis (Hayashi et al., 1997; Hayashi, 2000; Faulds and Meekings, 2013).
**Pharmacologically Induced Hypothermia: a Potential Therapeutic Strategy and Implication in Clinical Stage**

**Limitations of physical cooling**

Therapeutic hypothermia has been proposed as a treatment for stroke and shown to be effective in preclinical and clinical studies. However, despite the obvious beneficial effects of therapeutic hypothermia, its clinical application has been limited due to multiple shortcomings. For patients, current hypothermia protocols, including ice cooling or cooling pads, are generally slow (2–8 hours) and cumbersome, or invasive in the case of endovascular cooling. The long course of surface cooling often requires the concomitant use of anesthetics and paralysis in order to curb shivering, which are performed with endotracheal intubation and ventilation, which carry side effects, such as pulmonary infections (Hemmern and Lyden, 2007). The invasive nature of endovascular cooling can result in increased risk of infections and bleeding, and is not as universally applicable, due to the need for a skilled medical personnel to perform the catheter placement (Glushakova et al., 2016). In addition, physical cooling (PC) evokes shivering responses, which is a defensive metabolic adaptation to cold, as well as peripheral vasocon-
This systemic response makes effective and accurate cooling difficult, and most often the cooling procedure has to be performed under general anesthesia or sedation reagents (Schwab et al., 1998a; Sessler, 2009). Another possible limitation of hypothermia is its association with systemic infections, including pneumonia and sepsis, although this side effect can be treatable (Hemmen et al., 2010; Geurts et al., 2014). Other potential side effects of hypothermic treatment includes hypothermia-induced diuresis, resulting in hypovolemia and electrolyte depletion, thrombocytopenia, and bradycardia (Schwab et al., 2001). Furthermore, while clinical trials have shown hypothermia to be a feasible treatment, there is conflicting data as to whether hypothermia can effectively improve functional outcomes (Krieger et al., 2001; Schwab et al., 2001; Polderman et al., 2002; De Georgia et al., 2004; Nielsen et al., 2013; Lyden et al., 2016). This is largely due to the plethora of parameters associated with TTM, aside from simply the temperature reduction. Even if patients undergo physical cooling to optimal temperatures of 33–35°C, other factors that could affect the outcomes include the severity, location and subtypes of the injury, the time of intervention, the speed/duration of the cooling treatment, and finally other pharmacological agents (e.g., anesthetics or paralytics) administered (Wan et al., 2014; Subramaniam et al., 2015). All of these factors contribute to the inconsistent findings, but they also provide tremendous potential for optimization of therapeutic hypothermia in order to ensure its efficacy.

Recent early pilot studies with clinical trials have provided modest evidence suggesting both the feasibility and efficacy of therapeutic hypothermia, especially when performed in conjunction with thrombolysis (Hemmen et al., 2010; Piironen et al., 2014). These studies have parlayed into a phase III multi-center randomized controlled trial, EuroHYP-1, and the results will have significant ramifications on the implementation of this clinical strategy (Worp et al., 2014). Nevertheless, considering the modest success associated with therapeutic hypothermia thus far, as well as the current ESO guidelines that discourage the use of current physical means of hypothermia to treat ischemic stroke, it is important to continue the exploration of other avenues that can induce hypothermia in safer and more efficient ways (Ntaios et al., 2015). This is important because it may be possible that the aforementioned limitations may be associated more or less with physical cooling, either with surface cooling or endovascular methods. Thus, increasing research attention has recently been drawn to pharmacological reagents that have shown cooling effects in animals and/or humans.

**Pharmacologically induced hypothermia**

Pharmacologically induced hypothermia (PIH), which targets the peripheral or central thermoregulatory mechanisms, has emerged as a more efficient and safer treatment for brain disorders (Choi et al., 2012; Wei et al., 2013; Cao et al., 2014; Lee et al., 2014). PIH allows for greater control of temperature changes necessary for TTM. More importantly, we have shown that a PIH therapy targeting the central thermoregulator may suppress external cooling-induced shivering and tachycardia and achieve more rapid and effective hypothermia (Feketa et al., 2013; Lee et al., 2016a). It is well known that shivering, as a physiological defense mechanism against body cooling, is a strong and troublesome reaction that is invariably coupled with physical cooling. This reaction often prevents effective and accurate control of hypothermic treatment. Normally, general anesthesia and/or sedation have to be applied to battle with shivering during physical cooling. PIH using hypothermic drugs acting at the central or peripheral thermoregulatory receptors/channels provides a mechanism-based strategy to eliminate cooling-associated shivering and other responses. This unique effect creates multimodal benefits, including the administration of hypothermic treatment in awake patients without the need for general anesthesia and the avoidance of a number of side effects seen with conventional physical cooling methods.

Currently, there are several major classes of pharmacological agents that are categorized based on their mechanisms of action and thermoregulation target: neurotensin, transient receptor potential vanilloid 1 (TRPV1), cannabinoid, opioid, thyroxine derivatives, dopamine, gas, and adenosine derivatives (Table 1). Other drugs, such as non-steroidal anti-inflammatory drugs (NSAIDs) that show mild TTM action have also been investigated in the context of therapeutic hypothermia but are not as effective for inducing and maintaining the minimum temperature reductions (Feigin et al., 2002). Our group has developed the second generation of hypothermic compounds acting as a selective neurotensin receptor 1 (NTR1) agonist that can pass through the BBB and efficiently reduce the body and brain temperature in a dose-dependent manner (Choi et al., 2012). For example, HPI-201 and HPI-363 (also known as ABS-201, ABS-363) are NTR1 agonists acting at the hypothalamic thermoregulatory set point. It possesses a high affinity for human NTR1, exhibits BBB permeability, and effectively induces regulated hypothermia in rodents, resulting in protective effects and improved functional recovery after ischemic or hemorrhagic stroke or TBI in mice (Hadden et al., 2005; Choi et al., 2012; Wei et al., 2013; Lee et al., 2014, 2016a, b). Other groups showed that an agonist at transient receptor potential cation channel subfamily vanilloid member 1 (TRPV1) can decrease temperature via regulation of the peripheral temperature sensitive channel and confer neuroprotective effects after stroke in animals (Feketa et al., 2013; Cao et al., 2014).

Overall, PIH confers several significant advantages over physical cooling that allow for more feasible clinical implementation. These include the targeting of the thermoregulatory center in the hypothalamus in order to decrease the cold set point to reduce compensatory physiological responses to hypothermia. These effects, such as shivering, piloerection, and vasoconstriction, cause discomfort for the patients.
and reduces the efficacy of hypothermia (Díaz and Becker, 2010). Importantly, PIH and physical cooling are not mutually exclusive, and the best paradigm may ultimately be a combination therapy of the two in order to create a reliable regimen that uses a lower minimum pharmacological dose (to mitigate potential side effects) to induce hypothermia, but that also dulls the cold response (Muzzi et al., 2013; Liu et al., 2016). Preliminary data has already suggested that combination therapy can provide synergistic effects that augment the benefits of either treatment alone (Lee et al., 2016a).

**Conclusion**

Therapeutic hypothermia is one of the most promising therapies for neuroprotection against brain injuries such as stroke. The mechanism of action is multifaceted. Therapeutic hypothermia provides a global brain protection rather than targeting a single pathways or a single gene. Therapeutic hypothermia can regulate multiple pathways including excitotoxicity, oxidative stress, apoptosis, autophagy and promote regenerative activities. We expect that these actions can be utilized to show synergistic effects with other neuroprotective treatments such as ITP and help to develop combinatory stroke therapy for clinical treatments. To this end, PIH has been demonstrated to be an effective and more efficient hypothermic therapy that shows high feasibility and translational potential for clinical applications. Further study will be needed to have an in-depth understanding of the multiple mechanisms underlying therapeutic hypothermia and reinforced efforts are necessary to verify the efficacy of PIH compounds in large animals such as non-human primates. It is expected that safer and more effective hypothermic therapies may help develop more clinical treatments for stroke and other intractable brain disorders.

**Author contributions:** JHL wrote the original draft; JZ carried out the revision and SPY participated in original writing and finalized the paper.

**Conflicts of interest:** Authors claim no conflicts of interest related to this work.

**References**

Adeoye O, Hornung R, Khatiri P, Kleindorfer D (2011) Recombiant tissue-type plasminogen activator use for ischemic stroke in the United States: a doubling of treatment rates over the course of 5 years. Stroke 42:1952-1955.

Adler M, Geller E, Rosow C, Cochin J (1988) The opioid system and temperature regulation. Ann Rev Pharmacol Toxicol 28:429-449.

Baggottini J, Manfredi JJ (2002) Multiple roles of the tumor suppressor p53. Curr Opin Oncol 14:86-91.

Baumann E, Preston E, Slinn J, Stanimirovic D (2009) Post-ischemic hypothermia attenuates loss of the vascular basement membrane proteins, agrin and SPARC, and the blood-brain barrier disruption after global cerebral ischemia. Brain Res 1269:185-197.

Benamar K, Geller EB, Adler MW (2002) Role of the nitric oxide pathway in k-opioid-induced hypothermia in rats. J Pharmacol Exp Ther 303:375-378.

Bissette G, Nemeroff CB, Loosen PT, Prange AJ, Lipton MA (1976) Hypothermia and intolerance to cold induced by intracranial administration of the hypothalamic peptide neurotensin. Nature 262:607-609.

Bonfilis PK, Reith J, Hasselhain NM, Johansen FF (2006) Estimation of the hypothemic component in neuroprotection provided by cannabinoids following cerebral ischemia. Neurochem Int 49:508-518.

Bosshenmeyer-Pourie C, Koziel V, DaVal J (2000) Effects of hypothermia on hypoxia-induced apoptosis in cultured neurons from developing rat forebrain: comparison with preconditioning. Pediatr Res 47:365-391.

Bowling H, Bhattacharya A, Klann E, Chao MV (2016) Deconstructing brain-derived neurotrophic factor actions in adult brain circuits to bridge an existing informational gap in neuro-cell biology. Neural Regen Res 11:363-367.

Campos F, Perez-Mato M, Aguilla J, Blanco M, Barral D, Almeda A, Brea D, Waeger C, Castillo J, Ramos-Cabrer P (2012) Glutamate excitotoxicity is the key molecular mechanism which is influenced by body temperature during the acute phase of brain stroke. PLoS One 7:e44191.

Cao Z, Balasubramanian A, Marrelli SP (2014) Pharmacologically induced hypothermia via TRPV1 channel agonism provides neuroprotection following ischemic stroke when initiated 90 min after reperfusion. Am J Physiol Regul Integr Comp Physiol 306:R149-R156.

Chamorro A, Dirmagi U, Urra X, Planas AM (2016) Neuroprotection in acute stroke: targeting excitotoxicity, oxidative and nitrosative stress, and inflammation. Lancet Neurol 15:869-881.

Che X, Ye W, Panga L, Wu DC, Yang YG (2001) Monocoye chemotactant protein-1 expressed in neurons and astrocytes during focal ischemia in mice. Brain Res 902:171-177.

Chen E, Friederman R, Cheng Q, Tuki F, Schin E, Kleinfeld D, Lyden PD (2009) Severe blood-brain barrier disruption and surrounding tissue injury. Stroke 40:e666-e674.

Chen W, Sun Y, Liu K, Sun X (2014) Autophagy: a double-edged sword for neuronal survival after cerebral ischemia. Neural Regen Res 9:1210-1216.

Cheng BC, Huang HS, Chao CM, Hsu CC, Chen CY, Chang CP (2013) Hypothermia may attenuate ischemia/reperfusion-induced myocardic cell death by reducing autophagy. Int J Caridiol 168:2064-2069.

Cheng YD, Al-Khoury L, Zivin JA (2004) Neuroprotection for ischemic stroke: two decades of success and failure. NeuroRx 1:36-45.

Cherry JD, Olschowa J, O’Banion MK (2014) Neuroinflammation and M2 microglia: the good, the bad, and the inflamed. J Neuroinflammation 11:98.

Choi DW (1992) Excitotoxic cell death. J Neurobiol 23:1261-1276.

Choi KE, Hall CM, Sun JM, Wei L, Mohamad O, Dix TA, Yu SP (2012) A novel stroke therapy of pharmacologically induced hypothermia after focal cerebral ischemia in mice. FASEB J 26:2799-2810.

Coassin M, Duncan KG, Bailey KR, Singh A, Schwartz DM (2010) Hypothermia reduces secretion of vascular endothelium growth factor by cultured retinal pigment epithelial cell. Br J Ophthalmol 94:1678-1683.

Colboc O, Costentin J (1980) Evidence for thermoregulatory dopamine receptors in the preoptic mediais nucleus of the rat hypothalamus. J Pharmacy Pharmacol 32:624-629.

Colburne F, Grooms SY, Zukin RS, Buchan AM, Bennett MV (2003) Hypothermia rescues hippocampal CA1 neurons and attenuates down-regulation of the AMPA receptor GluR2 subunit after forebrain ischemia. Proc Natl Acad Sci U S A 100:2906-2910.

D’Cruz BJ, Fertig KC, Filiano AJ, Hicks SD, DeFranco DB, Callaway CW (2002) Hypothemic reperfusion after cardiac arrest augments brain-derived neurotrophic factor activation. J Cereb Blood Flow Metab 22:843-851.

Dae MW, Gao DW, Ursell PC, Stillson CA, Sessler DI (2003) Safety and efficacy of endovascular cooling and rewarthing for induction and reversal of hypothermia in human-sized pigs. Stroke 34:734-738.

Darwaheh R, Yan Y (2013) Mild hypothermia as a treatment for central nervous system injuries: Positive or negative effects. Neural Regen Res 8:2677-2686.

David HN, Haelwelyn B, Chazalival L, Lecoq M, Dougoulet M, Rioso JJ, Abraini JH (2009) Post-ischemic helium provides neuroprotection in rats subjected to middle cerebral artery occlusion-induced ischemia by producing hypothermia. J Cereb Blood Flow Metab 29:1159-1165.

De Georgia MA, Krieger D, Abou-Chedid A, Devlin T, Jauss M, Davis S, Koroshetz W, Rordorf G, Warach S (2004) Cooling for acute ischemic brain damage (COOL AID) a feasibility trial of endovascular cooling. Neurology 63:312-317.
Lee et al. / Neural Regeneration Research. 2017;12(3):341-350.
Lee JH, Wei L, Gu X, Won S, Wei ZZ, Dix TA, Yu SP (2016a) Improved therapeutic benefits by combining physical cooling with pharmacological hypothermia after severe stroke in rats. Stroke 47:1907-1913.

Lee JH, Wei ZZ, Cao W, Won S, Gu X, Winter M, Dix TA, Wei L, Yu SP (2016b) Regulation of therapeutic hypothermia on inflammatory cytokines, microglia polarization, migration and functional recovery after ischemic stroke in mice. Neurobiol Dis 69:248-260.

Leker RR, Gai N, Mechoulam R, Ovadia H (2003) Drug-induced hypothermia reduces ischemic damage. Stroke 34:2000-2006.

Li J, Benashski S, McCullough LD (2011) Post-stroke hypothermia provides neuroprotection through inhibition of AMP-activated protein kinase. J Neurotrauma 28:1281-1288.

Liu K, Khan H, Geng X, Zhang J, Ding Y (2016) Pharmacological hypothermia: a potential for future stroke therapy? Neurol Res 38:478-490.

Liu L, Kim JY, Koike MA, Yoon YJ, Tang XN, Ma H, Lee H, Steinberg MJ, Lee et al. / Neural Regeneration Research. 2017;12(3):341-350.

Maxwell WL, MacKinnon MA, Smith DH, McIntosh TK, Graham DI (2000) Apoptotic and anti-apoptotic synaptic signaling mechanisms. Brain Pathol 10:300-312.

Matsuo T, Kakeda T (2008) IL-10 production is reduced by hypothermia but augmented by hyperthermia in rat microglia. J Neurotrauma 25:709-715.

Mattson MP (2000) Apoptotic and anti-apoptotic synaptic signaling mechanisms. Brain Pathol 10:300-312.

Meltzer FT, Mirzadeh Z, Alvarez-Buylla A (2007) Mosaic organization of neural stem cells in the adult brain. Science 317:381-384.

Murphy PJ, Wynn TA (2011) Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol 11:723-737.

Muzii M, Blasi F, Chiarugi A (2013) AMP-dependent hypothermia affords protection from ischemic brain injury. J Cereb Blood Flow Metab 33:171-174.

Muzii M, Felici R, Cavone L, Gerace E, Minassi A, Appendino G, Monfoni F, Chiarugi A (2012) Ischemic neuroprotection by TRPV1 receptor-induced hypothermia. J Cereb Blood Flow Metab 32:978-982.

Nagel S, Su Y, Horstmann S, Heiland S, Gardner H, Kozl J, Martini-Torres FJ, Wagner S (2008) Minocycline and hypothermia for reperfusion injury after focal cerebral ischemia in the rat: effects on BBB breakdown and MMP expression in the acute and subacute phase. Brain Res 1188:198-206.

Nakashima K, Todd MM (1996) Effects of hypothermia on the rate of excitatory amino acid release after ischemic depolarization. Stroke 27:913-918.

Nicholson CK, Calvert JW (2010) Hydrogen sulfide and ischemia-reperfusion injury. Pharmacol Rev 62:289-297.

Nielsen N, Weterslev J, Cronberg T, Erlinge D, Gasche Y, Hassager C, Horn J, Hovdenes I, Jørgensen DJ, Kuiper M, Pellis T, Stammet J, Westerlund J, Wanstcher M, Wise MP, Åneman A, Al-Subaie N, Boesgaard S, et al. (2013) Targeted temperature management at 33°C versus 36°C after cardiac arrest. N Engl J Med 369:2197-2206.

Parratt A, Bechmann I, Pivniva T, Mahlo J, Biber K, Nolte C, Kovac AD, Gerard C, Boddeke HW, Nitsch R, Kettemann H (2004) CXCR3-dependent microglial recruitment is essential for dendrite loss after brain lesion. J Neurosci 24:8500-8509.

Ravil S, Cabassa J, Geller EB, Adler MW (2002) CB1 receptors in the preoptic anterior hypothalamus regulate WIN 55212-2 ([4,5-dihydro-2-methyl-4(4-morpholinylmethyl)-1-(1-naphthalenyl-carbonyl)-6H-pyrrrolo[3,2,1ij]quinolin-6-one]-induced hypothermia. J Pharmacol Exp Ther 301:963-968.

Rittner JE, Korbirouk I, Hull-Ryde EA, Jin J, Janzen WP, Feye SV, Zylka MJ (2012) AMP is an adenosine A1 receptor agonist. J Biol Chem 287:5301-5309.

Roelfsema V, Gunn AJ, Breier BH, Quaedackers J, Bennet L (2005) The effect of mild hypothermia on insulin-like growth factors after severe asphyxia in the preterm fetal sheep. J Soc Gynecol Invest 12:232-237.

Schwab S, Repine MJ, Hicks SD, DeFranco DB, Callaway CW (2004) Regional changes in glial cell-line-derived neurotrophic factor after cardiac arrest and hypothermia in rats. Neurosci Lett 368:135-139.

Schwab S, Schwarz S, Springer M, Keller E, Bertram M, Hacks W (1998b) Moderate hypothermia in the treatment of patients with severe middle cerebral arterial infarction. Acta Neurochir Suppl 71:131-134.

Schwab S, Schwarz S, Springer M, Keller E, Bertram M, Hacks W (1998b) Moderate hypothermia in the treatment of patients with severe middle cerebral arterial infarction. Stroke 29:2461-2466.

Siegfried G, Georgiadis D, Berrouschot J, Schelling PD, Graffagnino C, Mayer SA (2001) Feasibility and safety of moderate hypothermia after massive hemispheric infarction. Stroke 32:2033-2035.

Seo JY, Kim YH, Kim JW, Kim SI, Ha KY (2015) Effects of therapeutic hypothermia on apoptosis and autophagy after spinal cord injury in rats. Spine (Phila Pa 1976) 40:883-890.

Sessler DI (2009) Thermoregulatory defense mechanisms. Crit Care Med 37:S202-310.

Sheng SP, Lei B, James ML, Lascola CD, Venkataraman TN, Jung JY, Maze M, Franks NP, Pearlstein RD, Sheng H, Warner DS (2012) Xenon neuroprotection in experimental stroke interactions with hypothermia and intracerebral hemorrhage. Anesth Analg 115:1267-1275.

Shohab N, Buchan AM, Hill MD, Canadian Alteplase for Stroke Effectiveness S (2011) Thrombolysis at 3-4.5 hours after acute ischemic stroke onset—evidence from the Canadian Alteplase for Stroke Effectiveness CASES (study). Cerebrovasc Dis 31:223-228.

Siejo BK, Bengtsson F, Grampp W, Theander S (1989) Calcium, excitotoxins, and neuronal death in the brain. Ann N Y Acad Sci 568:234-251.

Sigg DC, Coles JA, Oeltgen PR, Iaizzo PA (2002) Role of δ-opioid receptor agonists on infant size reduction in swine. Am J Physiol Heart Circ Physiol 282:H1953-H1960.

Silagi G, Colbourne F (2011) Therapeutic hypothermia influences cell genesis and survival in the rat hippocampus following global ischemia. J Cereb Blood Flow Metab 31:1725-1735.

Strecker JK, Minepurp J, Schuster-Water B, Konstantinidis K, Gess B, Schabitz WR, Schillig M (2013) Monocyte chemoattractant protein-1 deficiency results in altered blood-brain barrier breakdown after experimental stroke. Stroke 44:2536-2544.
Subramaniam A, Tiruvoipati R, Botha J (2015) Is cooling still cool? Ther Hypothermia Temp Manag 5:13-16.
Sugerman NT, Abella BS (2009) Hospital-based use of therapeutic hypothermia after cardiac arrest in adults. J Neurotrauma 26:371-376.
Suzuki N, Suzuki M, Murakami K, Hamajo K, Tsukamoto T, Shimjojo M (2012) Cerebroprotective effects of TAK-937, a cannabinoid receptor agonist, on ischemic brain damage in middle cerebral artery occluded rats and non-human primates. Brain Res 1430:93-100.
Tahir RA, Pananey AH (2016) Therapeutic hypothermia and ischemic stroke: A literature review. Surg Neurol Int 7:381-386.
Takami S, Minami M, Nagata I, Namura S, Satoh M (2001) Chemokine receptor antagonist peptide, viral MIP-II, protects the brain against focal cerebral ischemia in mice. J Cereb Blood Flow Metab 21:1430-1435.
Tao Z, Zhao Z, Lee CC (2011) 5’-Adenosine monophosphate induced hypothermia reduces early stage myocardial ischemia/reperfusion injury in a mouse model. Am J Transl Res 3:331-361.
Torok E, Klopotowski M, Trabold R, Thal SC, Plesnila N, Scholler K (2009) Mild hypothermia (33 degrees C) reduces intracranial hypertension and improves functional outcome after subarachnoid hemorrhage in rats. Neurosurgery 65:352-359; discussion 359.
Torup L, Borsdal J, Sager T (2003) Neuroprotective effect of the neurotoxin analogue JMV-449 in a mouse model of permanent middle cerebral ischaemia. Neurosci Lett 351:173-176.
vander Worp HB, Sena ES, Donnan GA, Howells DW, Macleod MR (2007) Hypothermia in animal models of acute ischaemic stroke: a systematic review and meta-analysis. Brain 130:3063-3074.
Vila N, Castillo J, Davalos A, Chamorro A (2000) Proinflammatory cytokines and early neurological worsening in ischemic stroke. Stroke 31:2325-2329.
Vosler PS, Logue ES, Repine MJ, Callaway GW (2005) Delayed hypothermia preferentially increases expression of brain-derived neurotrophic factor exon III in rat hippocampus after asphyxial cardiac arrest. Brain Res Mol Brain Res 135:21-29.
Wan YH, Nie C, Wang HL, Huang CY (2014) Therapeutic hypothermia (different depths, durations, and rewarming speeds) for acute ischemic stroke: a meta-analysis. J Stroke Cerebrovasc Dis 23:1873-1880.
Wang HK, Park UJ, Kim SY, Lee JH, Kim SU, Gwag BJ, Lee YB (2008) Free radical production in CA1 neurons induces MIP-1alpha expression, microglia recruitment, and delayed neuronal death after transient forebrain ischemia. J Neurosci 28:1721-1727.
Wang Q, Li A, Zhi D, Huang H (2007) Effect of mild hypothermia on glucose metabolism and glycerol of brain tissue in patients with severe traumatic brain injury. Chinese J Traumatol 10:236-249, 249-252.
Wang Y, Zhang H, Wang Z, Geng Z, Liu H, Yang H, Song P, Liu Q (2012) Therapeutic effect of nerve growth factor on cerebral infarction in dogs using the hemisphere abnormal volume ratio of diffusion-weighted magnetic resonance imaging. Neurosurg Res 1430:93-100.
Wei S, Sun J, Li J, Wang L, Hall CL, Dix TA, Mohamad O, Wei L, Yu SP (2013) Acute and delayed protective effects of pharmacologically induced hypothermia in an intracerebral hemorrhage stroke model of mice. Neuroscience 252:489-500.
Wilson S, Raghupathi R, Saatman KE, Mackinnon MA, McIntosh TK, Graham DY (2004) Continued in situ DNA fragmentation of microrna/macrophages in white matter weeks and months after traumatic brain injury. J Neurotrauma 21:239-250.
Won SJ, Kim DY, Gwag BJ (2002) Cellular and molecular pathways of ischemic neuronal death. J Biochem Mol Biol 35:67-86.
van der Worp HB, Macleod MR, Bath PM, Demotes M, Durand-Zaleski I, Gebhardt B, Gluud C, Kolimar R, Krieger DW, Lees KR, Molina C, Montaner J, Roine RO, Peterson J, Staykov D, Szabo I, Wardlaw JM, Schwab S; EuroHYP-1 investigators (2014) EuroHYP-1: European multicenter, randomized, phase III clinical trial of therapeutic hypothermia plus best medical treatment vs. best medical treatment alone for acute ischemic stroke. Int J Stroke 9:642-645.
Writing Group Members, Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, Das SR, de Ferranti S, Després JP, Fullerton HJ, Howard VJ, Huffman MD, Isaai CR, Jiménez MC, Judd SE, Kissela BM, Lichtman JH, Lisabeth LD, Liu S, et al. (2016) Heart disease and stroke statistics—2016 update: A report from the American Heart Association. Circulation 133:e238-310.
Wurzelmann MR, Remelka J, Sun D (2017) Therapeutic potential of brain-derived neurotrophic factor (BDNF) and a small molecular mimics of BDNF for traumatic brain injury. Neural Regen Res 12:7-12.
Xiao G, Guo Q, Shu M, Xie X, Deng J, Zhu Y, Wan C (2013) Safety profile and outcome of mild therapeutic hypothermia in patients following cardiac arrest: systematic review and meta-analysis. Emerg Med J 30:99-101.
Xie YC, Li CY, Li T, Nie DY, Ye F (2007) Effect of mild hypothermia on angiogenesis in rats with focal cerebral ischemia. Neurosci Lett 422:87-90.
Xiong X, Barreto GE, Xu L, Ouyang YB, Xie X, Giffard RG (2011) Increased brain injury and worsened neurological outcome in interleukin-4 knockout mice after transient focal cerebral ischemia. Stroke 42:2026-2032.
Xu L, Yenari MA, Steinberg GK, Giffard RG (2002) Mild hypothermia reduces apoptosis of mouse neurons in vitro early in the cascade. J Cereb Blood Flow Metab 22:21-28.
Xu L, Wang P, Zhao Z, Cao T, He H, Luo Z, Zhong J, Gao F, Zhu Z, Li L, Yan Z, Chen J, Ni Y, Liu D, Zhu Z (2011) Activation of transient receptor potential vanilloid 1 by dietary capsaicin delays the onset of stroke in stroke-prone spontaneously hypertensive rats. Stroke 42:3245-3251.
Yenari MA, Han HS (2012) Neuroprotective mechanisms of hypothermia in brain ischemia, Nat Rev Neurosci 13:267-278.
Zhang M, Li W, Niu G, Leak RK, Chen J, Zhang F (2013a) ATP induces mild hypothermia in rats but has a strikingly detrimental impact on focal cerebral ischemia. J Cereb Blood Flow Metab 33:e1-10.
Zhang M, Wang H, Zhao J, Chen C, Leak RK, Xu Y, Vosler P, Chen J, Gao Y, Zhang F (2013b) Drug-induced hypothermia in stroke models: does it always protect? CNS Neurol Disord Drug Targets 12:371-380.
Zhang Z, Chen Y, Kirsch JR, Young TJ, Trarshman Y, Koehler RC, Hurn PD, Bharadwaj A (2003) Kappa-opioid receptor selectivity for ischemic neuroprotection with BRL 52537 in rats. Anesth Analg 97:1776-1783.
Zhao H, Steinberg GK, Sapolsky RM (2007a) General versus specific actions of mild-moderate hypothermia in attenuating cerebral ischemic damage. J Cereb Blood Flow Metab 27:1879-1894.
Zhao H, Yenari MA, Sapolsky RM, Steinberg GK (2004) Mild postischemic hypothermia prolongs the time window for gene therapy by inhibiting cytochrome C release. Stroke 35:572-577.
Zhang H, Wang JQ, Shimohata T, Sun G, Yenari MA, Sapolsky RM, Steinberg GK (2007b) Conditions of protection by hypothermia and effects on apoptotic pathways in a rat model of permanent middle cerebral artery occlusion. J Neurosurg 107:636-641.